In POD1UM-204, patients with advanced EC with disease progression on or after >1 platinum-based regimen are enrolled in four treatment groups based on prior immunotherapy exposure and tumor characteristics, such as MSH-I, dMMR, ultra-mutated POLE, and FGFR mutation. The gene discussed is POLE; the disease is neoplasm.